4.4 Article

Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy

期刊

ANTI-CANCER DRUGS
卷 16, 期 5, 页码 587-591

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001813-200506000-00015

关键词

chemotherapy; oxaliplatin; neuropathy; neurotoxicity; topiramate; venlafaxine

向作者/读者索取更多资源

Venlafaxine (Effexor; Wyeth Lederle), a serotoninergic-like anti-depressant, and Topiramate (Epitomax; Jansen Cilag), a new anti-epileptic drug, share some evidence of clinical activity in the treatment of neuropathic pain. Several anticancer agents have neurosensory toxicity as limiting toxicity of their repeated administration. One of the most recent and the most widely used is oxaliplatin. No medication is presently known to be active against oxaliplatin permanent neurosensory toxicity. We observed that venlafaxine hydrochloride or low-dose topiramate could be active against the permanent neuropathy-related symptoms of oxaliplatin. Both agents allowed pain relief and a significant autonomy improvement. These preliminary results invite us to evaluate further venlafaxine hydrochloride and topiramate for the treatment of permanent anti-cancer chemotherapy-induced neuropathies. Anti-Cancer Drugs 16:587-591 (c) 2005 Lippincott Williams & Wilkins.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据